Dermatology
Latest News
Novel hydrogel holds promise for skin regeneration
The first clinical trials for treating complex diabetic wounds are planned for early 2024.
Latest News
Multicenter study aims to find new treatments for hidradenitis suppurativa
The effort includes collection of biospecimens for translational studies to drive drug development.
Latest News
Systematic review spotlights the use of nutraceuticals for acne
Zinc was the most studied nutraceutical, but there was substantial heterogeneity in the results.
Latest News
FDA approves fixed dose combination topical treatment for acne
The new treatment combines three approved acne products for once-daily use.
Latest News
Recombinant IL-2 shows potential in atopic dermatitis
Rezpegaldesleukin is now being evaluated in a phase 2b study for moderate to severe atopic dermatitis, and a phase 2b trial for alopecia areata is...
Latest News
Treatment options for vitiligo reviewed
Principles of vitiligo treatment are to stop immune destruction and to stimulate melanocyte differentiation, migration, and melanin production, Dr...
Feature
Psoriatic disease: Researchers seek a PsA diagnostic test, phenotype-targeted treatment
Researchers described ongoing work to “understand the discrete and overlapping endotypes that underlie the phenotypes” of psoriatic disease and to...
Latest News
Teledermatology model takes hold with grants to underserved areas
George Washington University’s successful teledermatology clinic will serve as model for programs in Los Angeles, Oregon, Miami, and Philadelphia...
Latest News
FDA proposes ban on hair straightener ingredients
The proposal specifies that formaldehyde would be banned, as well as other chemicals that release formaldehyde, such as methylene glycol.
Feature
Researchers link two genes to Raynaud’s disease
The discovery will hopefully lead to new therapeutic avenues for the condition, experts say.
Latest News
FDA approves bimekizumab for moderate to severe plaque psoriasis in adults
With this approval, bimekizumab becomes the only interleukin (IL)-17A and IL-17F inhibitor approved for the treatment of these patients.